This trial is active, not recruiting.

Condition skin cancer
Treatments carboplatin, radiotherapy
Phase phase 3
Sponsor Trans-Tasman Radiation Oncology Group (TROG)
Collaborator Princess Alexandra Hospital, Brisbane, Australia
Start date April 2005
End date December 2016
Trial size 321 participants
Trial identifier NCT00193895, TROG 05.01


The primary objective of the trial is to determine, in patients who have undergone surgery with curative intent for high-risk CSCC of the head and neck, whether there is a difference in time to loco-regional relapse between patients treated with post-operative concurrent chemo-radiotherapy ,consisting of Carboplatin, and post-operative radiotherapy alone. The target sample size for the trial is 266 patients and will take 3-4 years to accrue, based on an anticipated accrual of 80 patients/year. A further 2 years follow up is required.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose treatment
(Active Comparator)
Radiotherapy alone (60Gy or 66Gy in 30-33 fractions 5-5/week)
radiotherapy Radiation
60 Gy OR 66Gy in 2Gy/fraction 5days/week
Radiotherapy plus chemotherapy (Radiotherapy 60Gy or 66Gy in 30-33 fractions 5/week + Carboplatin (AUC 2) intravenously weekly)
carboplatin Carboplatin Ebewe, Injection
Carboplatin will commence with a dose calculated to target an AUC of 2.0. A maximum of 6 doses of weekly Carboplatin will be given. Carboplatin will be administered intravenously over 20-30 minutes prior to radiation therapy.
radiotherapy Radiation
60 Gy OR 66Gy in 2Gy/fraction 5days/week

Primary Outcomes

Loco-regional Control
time frame: The date of primary outcome analysis will occur when the final patient has reached a minimum 2 years follow-up.

Secondary Outcomes

Disease Free Survival
time frame: The date of analysis will occur when the final patient has reached a minimum 2 years follow-up.
Overall Survival
time frame: The date of analysis will occur when the final patient has reached a minimum 2 years follow-up.
Quality of Life
time frame: The date of analysis will occur when the final patient has reached a minimum 2 years follow-up.
Treatment-related Late Effects
time frame: The date of analysis will occur when the final patient has reached a minimum 2 years follow-up.

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Histologically proven SCC - Patients have undergone either: - Resection of the primary lesion - Any type of parotidectomy (superficial, total, partial, etc.) - Any type of neck dissection(s) - High risk feature(s); Advanced primary disease or high risk nodal disease High Risk Nodal Disease - Intra-parotid nodal disease (any number or size, with/without extracapsular extension, with/without an identifiable index lesion) - Cervical nodal disease with a synchronous index lesion or previously resected cutaneous primary tumour (<5 years) within the corresponding nodal drainage and a mucosal primary has been excluded with at least a CT +/- MRI and panendoscopy* *For cervical nodal disease to be eligible there must be at least one of the following criteria: - > 2 nodes - largest node > 3 cm - Extracapsular extension Advanced Primary Disease (TNM 6th Edition 2002) (Appendix 1) - T3-4 primary disease (cartilage, skeletal, muscle, bone involvement, > 4 cm) of the head and neck including lip, nose and external auditory canal with or without nodal disease - In transit metastases (metastases between the primary site and the adjoining nodal basin) - Age > 18 years - Written informed consent - ECOG <= 2 - Absolute neutrophil count > 1.5 X 10^9/L, platelet count > 100 X 10^9/L, and haemoglobin > 10 g/dL (pre-radiotherapy blood transfusion to elevate the haemoglobin > 10 g/dL is permissible) - Calculated creatinine clearance (Cockcroft-Gault) >= 40 mL/min - Available for follow-up for up to 5 years - Life expectancy greater than 6 months Exclusion Criteria: - Intercurrent illness that will interfere with either the chemotherapy or radiotherapy such as immunosuppression due to medication or medical condition - Metastasis(es) below the clavicles - Previous radical radiotherapy to the head and neck, excluding treatment of an early glottic cancer greater than or equal to 2 years ago and superficial radiotherapy to cutaneous SCC or Basal cell carcinoma - High risk for poor compliance with therapy or follow-up as assessed by investigator - Pregnant or lactating women - Patients with prior cancers, except: those diagnosed > 5 years ago with no evidence of disease recurrence and clinical expectation of recurrence of less than 5%; or successfully treated Level 1 cutaneous melanomas or early glottic cancer > 2 years ago; or non-melanoma skin cancer; or carcinoma in situ of the cervix. - Low risk cervical nodal disease* without advanced primary disease *Low risk cervical nodal disease is defined as the presence of all of the following criteria: - single nodal metastasis - greater then or equal to 3cm, - no extracapsular extension

Additional Information

Official title Post-operative Concurrent Chemo-radiotherapy Versus Post-operative Radiotherapy in High-risk Cutaneous Squamous Cell Carcinoma of the Head and Neck
Description Two in every 3 Australians will be affected by skin cancer over their lifetime. The prevalence of skin cancer will continue to increase due to the ageing population and represents a significant problem in our community. Cure of early (T1-2) de novo cutaneous squamous cell carcinoma (CSCC) treated with either curative intent surgery or radiotherapy is 85-100%. However, the cure rate for locally advanced, recurrent, or metastatic disease to regional nodes following surgery alone are much lower, in the order of 20-70%. Metastatic CSCC is the most common malignancy of the parotid region in Australia. The 5 year loco-regional control with surgery alone is in the order of 40%-45%. The addition of post-operative radiotherapy improves loco-regional control by 15-20%, and is therefore considered the standard of care in this group of patients. Recent data have shown that synchronous post-operative chemo-radiotherapy is superior to post-operative radiotherapy alone in "high-risk" mucosal head and neck squamous cell carcinoma (HNSCC). However, to date, there is no evidence from randomised trials that such a benefit exists in CSCC of the head and neck. At present there is little consensus amongst clinicians in Australia as to who should receive post-operative chemo-radiotherapy in CSCC. Although tumour control rates may be improved, the addition of chemotherapy may also significantly increase treatment related toxicity. Nonetheless, some centres have adopted the use of post-operative chemo-radiotherapy in selected patients with CSCC based on extrapolation from mucosal sites. This has resulted in a wide variability in practice for this disease. Australia is uniquely placed to perform such a trial comparing post-operative chemo-radiotherapy to post-operative radiotherapy alone in high-risk CSCC due to the high rate of skin cancer. Currently there are limited data to guide management of patients with resected CSCC who are at high risk for recurrence. While it is reasonable to hypothesize that concurrent chemotherapy in this setting will confer a similar benefit to that seen in mucosal HNSCC, this can only be established by a randomized trial as proposed. If the addition of chemotherapy is shown to be beneficial and safe, then these results are likely to be translated into standard practice both nationally and internationally quite rapidly. On the other hand, if the treatment is found to be ineffective then patients will be spared the unnecessary toxicity and inconvenience associated with the addition of chemotherapy. A further important aspect of this trial will be the assessment of patient-related outcomes using a validated quality of life questionnaire. It will be important to ascertain whether any improvement in locoregional control due to the addition of chemotherapy, is also associated with improvement in quality of life compared to the control arm.
Trial information was received from ClinicalTrials.gov and was last updated in August 2015.
Information provided to ClinicalTrials.gov by Trans-Tasman Radiation Oncology Group (TROG).